BerGenBio Appoints Olav Hellebø as CEO PR Newswire BERGEN, Norway, Nov. 20, 2024 BERGEN, Norway, Nov. 20, 2024 /PRNewswire/ -- BerGenBio ASA...
BerGenBio announces clinical data presentations highlighting the activity of its selective AXL inhibitor bemcentinib in Non-Small Cell Lung...
BerGenBio ASA: Approval and publication of prospectus for the preferential Rights Issue PR Newswire BERGEN, Norway, May 26, 2023 NOT FOR RELEASE...
BerGenBio ASA: Proposed partially underwritten rights issue PR Newswire BERGEN, Norway, April 25, 2023 NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY...
BerGenBio Presents Data on STK11 Loss of Function and AXL Activation at AACR PR Newswire BERGEN, Norway, April 18, 2023 In addition to STK11...
BerGenBio Announces First Patient Dosed in Phase 1b/2a Trial Evaluating Bemcentinib in 1st Line Non-Small Cell Lung Cancer with STK11...
BerGenBio Reports Fourth Quarter 2022 Financial Results and Provides Business Update PR Newswire BERGEN, Norway, Feb. 16, 2023 BERGEN, Norway...
BerGenBio Announces Positive Data From Phase 2 Trial of Bemcentinib in Combination with Pembrolizumab in 2L+ NSCLC Patients PR Newswire BERGEN...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads